Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 101

Sort by

Sort Order Select

Journal Articles

Favorable preliminary safety and efficacy of mosunetuzumab plus ICE or DHAX salvage chemotherapy in relapsed/refractory large B-cell lymphoma

David Russler-Germain, Hunter Cochran, Fei Wan, Amalia Dubois, Chaz Moreno, Francesca Loyet, Dilan Patel, Brad Kahl, Todd Fehniger, Amanda Cashen, Armin Ghobadi, Neha Mehta-Shah, Nancy Bartlett

Blood (2025) 146 (Supplement 1): 5508.

https://doi.org/10.1182/blood-2025-5508

Published: 2025

Journal Articles

Subgroup analysis based on prior treatment from the Phase 3 allele study of tabelecleucel for epstein-barr virus-driven post-transplant lymphoproliferative disease

Sarah Nikiforow, Kris Mahadeo, Sridhar Chaganti, Amer Beitinjaneh, Sylvain Choquet, Daan Dierickx, Armin Ghobadi, Roberta Valenti, Anke Friedetzky, Sandrine Roye, Ran Reshef, Susan Prockop, Robert Baiocchi

Blood (2025) 146 (Supplement 1): 1934.

https://doi.org/10.1182/blood-2025-1934

Published: 2025

Journal Articles

primary analysis of Phase ib trial of duvelisib for cytokine release syndrome prophylaxis in patients undergoing chimeric antigen receptor T cell therapy for non-hodgkins lymphoma

Michael Slade, Michael Rettig, Parmeshwar Amatya, Zachary Crees, Brad Kahl, Neha Mehta-Shah, Dilan Patel, David Russler-Germain, Nancy Bartlett, Amanda Cashen, Iskra Pusic, Geoffrey Uy, John DiPersio, Armin Ghobadi

Blood (2025) 146 (Supplement 1): 929.

https://doi.org/10.1182/blood-2025-929

Published: 2025

Journal Articles

A Phase 1 study evaluating NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel (tisa-cel), post-axicabtagene ciloleucel (axi-cel), or post-lisocabtagene maraleucel (liso-cel) in Relapsed/Refractory large B-cell lymphoma

Zachary Crees, Armin Ghobadi, Elizabeth Budde, Ahmed Galal, Chenyu Lin, Donghoon Choi, Sun-Kyoung Im, Hye Jeong, Alex Oh, Michael Rettig, John DiPersio

Blood (2025) 146 (Supplement 1): 926.

https://doi.org/10.1182/blood-2025-926

Published: 2025

Journal Articles

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Blood (2025) 146 (Supplement 1): 667.

https://doi.org/10.1182/blood-2025-667

Published: 2025

Journal Articles

WU-CART-007, a CD7-directed allogeneic CAR-T cell therapy for R/R T-cell acute lymphoblastic leukemia/lymphoma: Phase 1/2 correlative data and long-term follow-up update

Alexander Hamil, Ibrahim Aldoss, Shannon Maude, Ashish Bajel, Armin Ghobadi, Rawan Faramand, Tom Leedom, Michael Rettig, Cherry Thomas, Ayman Kabakibi, Deepa Bhojwani

Blood (2025) 146 (Supplement 1): 4163.

https://doi.org/10.1182/blood-2025-4163

Published: 2025

Journal Articles

Favorable safety and efficacy in a phase II trial using duvelisib maintenance after autologous stem cell transplant in T-cell and B-cell non-Hodgkin lymphomas

Hunter Cochran, Raya Saba, Ningying Wu, Neha Mehta-Shah, Armin Ghobadi, John DiPersio, Amanda Cashen

Blood (2025) 146 (Supplement 1): 1860.

https://doi.org/10.1182/blood-2025-1860

Published: 2025

Journal Articles

Baseline immune and proteomic profiling predicts response and resistance to CD19 CAR T-cell therapy in B-cell non-Hodgkin lymphoma: Insights from a decentralized manufacturing clinical trial

Arun Arunachalam, Jessica Kerr, Jane Reese, Armin Ghobadi, David Wald, Rimas Orentas, Boro Dropulic, Paolo Caimi, Marcos de Lima, J. Joseph Melenhorst

Blood (2025) 146 (Supplement 1): 567.

https://doi.org/10.1182/blood-2025-567

Published: 2025

Journal Articles

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

Blood (2025) 146 (10): 1163–1173.

https://doi.org/10.1182/blood.2025028387

Published: 2025

Includes: Supplemental data

Journal Articles

Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P. Rettig, Reyka G. Jayasinghe, Feng Gao, Jeremy Eisele, Leah Gehrs, Julie Ritchey, Jaebok Choi, Camille N. Abboud, Iskra Pusic, Meagan Jacoby, Peter Westervelt, Matthew Christopher, Amanda Cashen, Armin Ghobadi, Keith Stockerl-Goldstein, Geoffrey L. Uy, John F. DiPersio

Blood (2025) 145 (13): 1382–1394.

https://doi.org/10.1182/blood.2024026497

Published: 2025

Includes: Supplemental data

Journal Articles

Long-Term Follow-up of Bendamustine/Rituximab - Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)

Blood (2024) 144 (Supplement 1): 4409.

https://doi.org/10.1182/blood-2024-198687

Published: 2024

Journal Articles

CTX112, a Next-Generation Allogeneic CRISPR-Cas9 Engineered CD19 CAR T Cell with Novel Potency Edits: Data from Phase 1 Dose Escalation Study in Patients with Relapsed or Refractory B-Cell Malignancies

Armin Ghobadi, Joseph P. McGuirk, Paul Shaughnessy, Constantine S. Tam, Melanie Allen, Chenyi Pan, Ziliang Li, William N. Stevens, Annie Weaver, Chan Y. Cheah

Blood (2024) 144 (Supplement 1): 4829.

https://doi.org/10.1182/blood-2024-203563

Published: 2024

Journal Articles

WUC007-03: A Phase 2 Study of Anti-CD7 Allogenic CAR-T Cells (WT-7) in Patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

Blood (2024) 144 (Supplement 1): 7225.

https://doi.org/10.1182/blood-2024-201825

Published: 2024

Journal Articles

WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results

Blood (2024) 144 (Supplement 1): 3450.

https://doi.org/10.1182/blood-2024-202005

Published: 2024

Journal Articles

Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients with CD7+ T-Cell Non-Hodgkin Lymphoma

Michael H. Kramer, Neha Mehta-Shah, Michael P. Rettig, Katherine Stricker, Melinda Harding, Feng Gao, Brett Ramsey, Peter Westervelt, Jan K Davidson-Moncada, Armin Ghobadi, John F. DiPersio, Geoffrey L. Uy

Blood (2024) 144 (Supplement 1): 2066.

https://doi.org/10.1182/blood-2024-200809

Published: 2024

Journal Articles

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

Jiasheng Wang, Shakthi Bhaskar, Babatunde Adedokun, Olalekan O. Oluwole, Leland Metheny, Amy Moskop, Caron A. Jacobson, Geoffrey Shouse, Sairah Ahmed, Armin Ghobadi, Saurabh Dahiya, Jiali Yan, Zhen-Huan Hu, Timothy Best, Jenny J. Kim, Debbie L. Mirjah, Marcelo C. Pasquini, Frederick L. Locke

Blood (2024) 144 (Supplement 1): 527.

https://doi.org/10.1182/blood-2024-209093

Published: 2024

Journal Articles

Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy

Armin Ghobadi, Robert Baiocchi, Amer M. Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, Xinyuan Duan, Laurence Gamelin, Kris Michael Mahadeo, Aditi Mehta, Sarah Nikiforow, Ran Reshef, Sandrine Roye, Jean-Claude Vedovato, Susan E Prockop

Blood (2024) 144 (Supplement 1): 70.

https://doi.org/10.1182/blood-2024-198159

Published: 2024

Journal Articles

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Blood (2024) 144 (Supplement 1): 224.

https://doi.org/10.1182/blood-2024-201694

Published: 2024

Journal Articles

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Blood (2024) 143 (26): 2722–2734.

https://doi.org/10.1182/blood.2023023447

Published: 2024

Includes: Supplemental data

Journal Articles

Phase II Trial of Duvelisib Maintenance after Autologous Stem Cell Transplant in T-Cell and B-Cell Non-Hodgkin Lymphomas: Results of Safety Lead in

Raya Saba, Neha Mehta-Shah, Armin Ghobadi, John F. DiPersio, Amanda F Cashen, Ningying Wu

Blood (2023) 142 (Supplement 1): 6245.

https://doi.org/10.1182/blood-2023-174109

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Favorable preliminary safety and efficacy of mosunetuzumab plus ICE or DHAX salvage chemotherapy in relapsed/refractory large B-cell lymphoma

Subgroup analysis based on prior treatment from the Phase 3 allele study of tabelecleucel for epstein-barr virus-driven post-transplant lymphoproliferative disease

primary analysis of Phase ib trial of duvelisib for cytokine release syndrome prophylaxis in patients undergoing chimeric antigen receptor T cell therapy for non-hodgkins lymphoma

A Phase 1 study evaluating NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel (tisa-cel), post-axicabtagene ciloleucel (axi-cel), or post-lisocabtagene maraleucel (liso-cel) in Relapsed/Refractory large B-cell lymphoma

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

WU-CART-007, a CD7-directed allogeneic CAR-T cell therapy for R/R T-cell acute lymphoblastic leukemia/lymphoma: Phase 1/2 correlative data and long-term follow-up update

Favorable safety and efficacy in a phase II trial using duvelisib maintenance after autologous stem cell transplant in T-cell and B-cell non-Hodgkin lymphomas

Baseline immune and proteomic profiling predicts response and resistance to CD19 CAR T-cell therapy in B-cell non-Hodgkin lymphoma: Insights from a decentralized manufacturing clinical trial

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation

Long-Term Follow-up of Bendamustine/Rituximab - Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)

CTX112, a Next-Generation Allogeneic CRISPR-Cas9 Engineered CD19 CAR T Cell with Novel Potency Edits: Data from Phase 1 Dose Escalation Study in Patients with Relapsed or Refractory B-Cell Malignancies

WUC007-03: A Phase 2 Study of Anti-CD7 Allogenic CAR-T Cells (WT-7) in Patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results

Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients with CD7+ T-Cell Non-Hodgkin Lymphoma

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Phase II Trial of Duvelisib Maintenance after Autologous Stem Cell Transplant in T-Cell and B-Cell Non-Hodgkin Lymphomas: Results of Safety Lead in

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only